While she attributes her survival to her oncologists and the care they provided, Maryclaire is quick to stress the difference between surviving and living, noting that it was her friends and family who gave her what she needed to truly recover.
Fall 2011
A mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.
Colorectal cancer is the third most common type of cancer diagnosed in the United States and is the third most common cause of cancer-related death.
The following cases were discussed at the 10th International Congress on the Future of Breast Cancer, which was held in Coronado, California, from August 4-7, 2011.
A look at the benefits of the chemoimmunotherapy rituximab for CLL and a look at the treatments and advances made in treating metastatic CRC.
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5